Business Context and Reporting Period
This Form 8-K is filed by Alpha Healthcare Acquisition Corp. (AHAC), a Special Purpose Acquisition Company (SPAC), on May 7, 2021. The filing addresses a non-reliance on previously issued financial statements for periods ending September 22, 2020, September 30, 2020, and December 31, 2020. The restatement is necessitated by an April 12, 2021 SEC Public Statement requiring SPAC warrants to be classified as liabilities measured at fair value rather than equity. Additionally, the filing notes an upcoming extraordinary general meeting to consider a business combination with Humacyte, Inc.
Key Financial Metrics and Adjustments
The filing details significant adjustments to financial statements for the "Affected Periods" due to the reclassification of warrants. The filing text does not provide current operating revenue or profit metrics as the company is a pre-combination SPAC; however, it provides the following adjusted balance sheet and income statement impacts:
- Warrant Liabilities: Reclassified from $0 to approximately $6.04 million (as of Dec 31, 2020), $7.79 million (as of Sep 30, 2020), and $8.01 million (as of Sep 22, 2020).
- Total Liabilities: Increased by approximately $6.15 million as of December 31, 2020, due to the warrant liability and adjustments to deferred underwriting fees.
- Net Income/Loss: The reclassification resulted in a change in fair value of warrant liabilities recorded as an expense. For the period from inception to December 31, 2020, the reported net loss of $(233,333) was adjusted to a net income of $1,419,645. This adjustment includes a $1,970,001 charge for the change in fair value of warrant liabilities and a $(317,023) offering expense.
- Stockholders' Equity: Total stockholders' equity remained effectively unchanged at approximately $5.0 million across the periods, though the composition shifted significantly between additional paid-in capital and accumulated deficit/retained earnings.
- Cash Flow: Net cash used in operating activities remained unchanged as the fair value adjustments are non-cash items.
Material Changes Versus Prior Period
The primary material change is the accounting treatment of warrants. Previously classified as equity, the warrants are now classified as derivative liabilities under ASC 815. This change impacts the balance sheet by increasing liabilities and reducing temporary equity (shares subject to redemption). On the income statement, the change introduces volatility through the "change in fair value of warrant liabilities" line item, which was previously non-existent. The filing explicitly states that the terms and quantum of the warrants have not changed; only the accounting classification has been updated to align with SEC guidance.
Guidance, Outlook, and Risks
Management Commentary: Management and the Audit Committee determined that the previous financial statements should no longer be relied upon. The company intends to file an amended Form 10-K for the year ended December 31, 2020, to reflect these changes. Management asserts that the restatement is not indicative of any change in business prospects and should not materially impact shareholder consideration of the proposed business combination with Humacyte, Inc.
Outlook: Going forward, the company expects to continue classifying warrants as liabilities, which will require ongoing fair value measurements and may adversely affect reported results of operations due to mark-to-market volatility.
Risks and Contingencies: The filing highlights standard SPAC risks, including the failure to obtain shareholder approval for the business combination, termination of the combination agreement, and the impact of the COVID-19 pandemic. It also notes the risk that forward-looking statements may prove inaccurate due to economic and regulatory uncertainties.
Important Facts for Investor Verification
- Verify the filing of the amended Form 10-K for the year ended December 31, 2020, to confirm the final restated financial figures.
- Confirm the status of the extraordinary general meeting regarding the business combination with Humacyte, Inc.
- Review the definitive proxy statement/prospectus (Form S-4) for detailed terms of the merger and updated risk factors.
- Monitor future quarterly reports for the impact of fair value adjustments on warrant liabilities on the company's net income.
- Note that the company is an emerging growth company and the restatement does not alter the underlying terms of the securities issued.